Novartis iptacopan reaches the primary end point in phase 2 clinical treatment of IgA nephropathy

Compilenewborn

On June 6, Novartis announced the primary endpoint data of a phase 2 study of iptacopan, the most advanced asset in its nephrology pipeline

In this study (NCT03373461), 112 patients with IgAN were randomly assigned to receive placebo and different doses of iptacopan

According to the Novartis announcement, this is the first report on the effectiveness and safety of selective inhibition of IgAN complement alternative pathways

In addition, based on the estimated glomerular filtration rate (eGFR), iptacopan also shows a tendency to stabilize kidney function

The chemical structure of iptacopan (picture source: medchemexpress.

IgAN belongs to complement-driven nephropathy (CDRD).

IgAN is a rare progressive kidney disease.

Iptacopan treats this type of kidney disease by targeting key drivers of CDRD

Although Novartis has 35 years of history in the treatment of kidney transplantation, iptacopan is the first drug in the company’s nephrology pipeline to address CDRD.

Reference source: Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)